Program
Anti-mutCALR/Anti-CD3 Bispecific Antibody INCA035784
Its studies are mostly in Myeloproliferative Disorders, led by Incyte.
Furthest: phase 1, since May 29, 20251 company-led study, 1 open or runningNext primary completion: Mar 14, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 11 open or running | phase 1since May 29, 2025 | May 29, 2025 | Mar 14, 2028phase 1 · NCT07008118 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 29, 2025First study: phase 1 study in Myeloproliferative DisordersFirst studyNCT07008118 · 120 planned · United States, Australia, Belgium and more
Ahead
- Mar 14, 2028Primary completion: phase 1 study in Myeloproliferative DisordersNCT07008118
TargetBeta
CD3E →read by rule
“A human Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody directed against both the mutated form of calreticulin (mutCALR; CALRmut) and the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on CD3E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etentamig | AbbVie | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| cevostamab | Hoffmann-La Roche | phase 3 | 8 |
| pasritamig | Johnson & Johnson | phase 3 | 5 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07008118Myeloproliferative Disorders · United States, Australia, Belgium and more | 1 | Recruiting | Mar 14, 2028 | 120 |
How it is read
Names in the registry
- “INCA035784”, 1 entry
Conditions, from the studies’ own filings
- Myeloproliferative Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.